Core Viewpoint - Shenzhen Wego Biological Products Co., Ltd. successfully won the bidding for state-owned construction land use rights in Guangming District, Shenzhen, for a price of RMB 60.4 million, which aligns with the company's strategic development plan for establishing an intelligent industrial base [1] Group 1: Land Acquisition Details - The company participated in the bidding for the land use rights of plot A628-0045, covering an area of 69,986.43 square meters, with a usage period of 30 years [1] - The funding for this land acquisition will come from the company's own or self-raised funds, and it does not constitute a related party transaction or a major asset restructuring as per regulations [1] Group 2: Strategic Implications - The acquisition of the land is intended to support the company's intelligent industrial base project, which is crucial for the company's high-quality development [1] - Upon completion of the new industrial base, the company plans to relocate its operations and will cooperate with the Guangming District government to facilitate the recovery of the existing factory site [1]

Core Viewpoint - The company is implementing an A-share option incentive plan aimed at enhancing corporate governance, attracting and retaining talent, and aligning the interests of shareholders, the company, and its core team for long-term development [3][4]. Group 1: Company Overview - Fosun Pharma was listed on the Shanghai Stock Exchange on August 7, 1998, and on the Hong Kong Stock Exchange on October 30, 2012 [2]. - As of August 22, 2025, the total share capital of the company is 2,670,429,325 shares, comprising 2,118,488,825 A-shares and 551,940,500 H-shares [2]. - The company operates in the fields of biochemical products, reagents, and related consulting services, among others [2]. Group 2: Incentive Plan Details - The total number of A-share options to be granted under the plan is capped at 5,726,100, which corresponds to 0.2144% of the company's total shares [4][5]. - The initial grant will consist of 4,580,900 options (80% of the total), while 1,145,200 options (20%) will be reserved for future grants [5][6]. - The A-share options will be sourced from shares repurchased from the secondary market [4][6]. Group 3: Objectives and Benefits - The plan aims to improve corporate governance and establish a long-term incentive mechanism to motivate executives and employees [3][4]. - It seeks to align the interests of shareholders, the company, and its core team, fostering a collective focus on the company's long-term growth [3][4]. Group 4: Grant and Exercise Conditions - The exercise price for the initial grant of A-share options is set at 27.93 yuan per share, based on the average trading price prior to the announcement [10]. - The plan includes a waiting period before options can be exercised, with specific timelines for different tranches of options [11][12]. - The plan stipulates that the options can only be exercised if certain financial performance criteria are met, including net profit and revenue from innovative drugs [14][15]. Group 5: Financial Impact and Accounting - The total estimated expense for the initial grant of 4,580,900 A-share options is projected to be 12.14 million yuan, which will be amortized over the plan's duration [30][31]. - The plan's implementation is expected to have a positive impact on the company's performance, potentially outweighing the associated costs [31].

Group 1 - The core viewpoint of the news is that Dongyangguang Changjiang Pharmaceutical Co., Ltd. is set to complete its last trading day on the Hong Kong Stock Exchange and will officially list as "Dongyangguang Pharmaceutical" on August 7, marking a significant innovation in the capital market with its "H-share absorption merger and introduction listing" model [1] - The company aims to achieve overall listing by merging its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, into its parent company, Dongyangguang Pharmaceutical, and issuing H-shares to minority shareholders of the subsidiary [1] - This move is seen as a way to break traditional capital operation barriers, reduce financial friction costs associated with acquisitions, and ensure shareholder rights, providing a reference model for industrial integration and international development [1] Group 2 - After listing in Hong Kong, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated-driven industrial upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [2] - The company focuses on drug research, production, and commercialization, specializing in innovative drugs, including improved new drugs, generic drugs, and biosimilars, with a strategic focus on infection, chronic diseases, and oncology [2] - Dongyangguang Pharmaceutical aims to establish a global operational platform and is committed to becoming a first-class international innovative pharmaceutical company [2]

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and officially launched the first case of "H-share absorption merger privatization + introduction listing" in the Hong Kong market [1] - The company plans to list on the Hong Kong Stock Exchange on August 7 under the name "Dongyangguang Pharmaceutical" (06887), creating a new paradigm for asset securitization in Chinese innovative pharmaceutical companies [1] - The absorption merger allows Dongyangguang Pharmaceutical to issue H-shares to minority shareholders of its subsidiary Dongyangguang Changjiang Pharmaceutical, facilitating overall listing [1] Group 2 - Industry insiders note that this move breaks traditional capital operation time barriers, reduces friction costs in acquisitions, and effectively safeguards shareholder rights [1] - The listing is seen as a response to the national strategy of optimizing capital market structure and provides a reference model for industrial integration and international development [1] - After the listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, creating a closed loop of "research and development - production - sales" [1][2] Group 3 - Dongyangguang Pharmaceutical is engaged in drug research, production, and commercialization, focusing on innovative drugs, including modified new drugs, generic drugs, and biosimilars [2] - The company adheres to principles of innovation, internationalization, and sustainability, with a strategic focus on treating infections, chronic diseases, and tumors [2] - Dongyangguang Pharmaceutical aims to become a world-class innovative pharmaceutical company with a mature and well-circulated business model [2]

7月29日，东阳光（600673）长江药业完成最后一个交易日，正式启动港股市场首例"H股吸收合并私有 化+介绍上市"的创新资本运作。按计划，公司将于8月7日以"东阳光药"(股票代码：06887.HK)为主体登 陆港交所主板，开创中国创新药企资产证券化新范式。 东阳光药吸收合并港股上市子公司东阳光长江药业实现整体上市，即拟上市主体东阳光药提交H股上市 申请，向其控股子公司东阳光长江药业小股东发行H股，换取前述小股东所持上市公司东阳光长江药业 股份。吸收合并完成后，东阳光药再通过介绍方式实现上市。 业内人士指出，此举不仅打破了传统资本运作方式的时间壁垒，降低企业收购产生的资金摩擦成本，实 现了资源整合与资本升级衔接，还能有效保证股东权益，为产业整合与国际化发展提供了可借鉴范例， 也是积极响应国家"优化资本市场结构"决策部署的生动体现。 东阳光药相关负责人表示，赴港上市后，东阳光药将获得长线资本支持，并有望实现一体化驱动完成产 业升级，即东阳光药研发能力、研发管线将与东阳光长江药业覆盖全国的销售网络形成合力，形成"研 发——生产——销售"闭环，打造全球化运营平台。 资料显示，东阳光药是一家从事药物的研发、生产和商业 ...

Group 1 - Dongyangguang Pharmaceutical has completed its last trading day and is set to launch on the Hong Kong Stock Exchange, marking the first instance of "H-share absorption merger privatization + introduction listing" in the market [1] - The company plans to list as "Dongyangguang Pharmaceutical" (stock code: 06887.HK) on August 7, 2023, creating a new paradigm for asset securitization among Chinese innovative pharmaceutical companies [1] - This listing does not involve new share issuance or fundraising; instead, it involves the absorption merger of its Hong Kong-listed subsidiary, Dongyangguang Changjiang Pharmaceutical, allowing small shareholders to exchange their shares for H-shares [1] Group 2 - Industry insiders note that this approach breaks traditional capital operation time barriers, reduces funding friction costs associated with acquisitions, and effectively safeguards shareholder rights [1] - The move is seen as a model for resource integration and capital upgrade, providing a reference for industrial consolidation and international development, aligning with national strategies to optimize capital market structures [1] - After the Hong Kong listing, Dongyangguang Pharmaceutical is expected to gain long-term capital support and achieve integrated industry upgrades, combining its R&D capabilities with the nationwide sales network of Dongyangguang Changjiang Pharmaceutical [1][2]